Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12283421 | 0.93 | PIM1 (0.52) | PIM1PIM3PIM2SYKCCRL2 | |
| SCHEMBL19386342 | 0.87 | PIM1 (0.53) | PIM1PIM3PIM2SYKMAP4K4 | |
| SCHEMBL2422222 | 0.86 | PIM1 (0.52) | PIM1PIM3PIM2MAP4K4CTSK | |
| SCHEMBL15100929 | 0.86 | PIM1 (0.52) | PIM1PIM3PIM2MAP4K4CTSK | |
| SCHEMBL2422225 | 0.86 | PIM1 (0.52) | PIM1PIM3PIM2MAP4K4CTSK | |
| SCHEMBL15101022 | 0.86 | PIM1 (0.52) | PIM1PIM3PIM2MAP4K4CTSK | |
| SCHEMBL28595540 | 0.85 | SYK (0.50) | PIM1PIM3PIM2SYKCTSK | |
| SCHEMBL28603231 | 0.85 | SYK (0.50) | PIM1PIM3PIM2SYKCCRL2 | |
| SCHEMBL28595542 | 0.85 | SYK (0.50) | PIM1PIM3PIM2SYKCTSK | |
| SCHEMBL28603234 | 0.85 | SYK (0.50) | PIM1PIM3PIM2SYKCCRL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107660199-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-3271352-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | PIM1 4678/4885PIM3 4115/4885PIM2 4457/4885 |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | PIM1 4678/4885PIM3 4115/4885PIM2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.